PBMC Humanized Mice
PBMC Humanized Mice Accelerate Drug Discovery and Development
Pre-clinical evaluation is a common and necessary step in the drug development process facilitating the evaluation of both the efficacy and toxicity of compounds in a living system. Utilizing PBMC humanized mice that most closely mimic the human immune system has become an industry standard particularly for immuno-oncology and cell therapy.
Prediction of therapeutic efficacy and success is more accurate when using such models and should be a cornerstone of your cell and gene therapy in vivo testing program. HemaCare and Charles River Laboratories have partnered to provide you with the tools you need to efficiently incorporate humanization studies into your workflow.
Quality Primary Cells for Engraftment
HemaCare offers high-quality primary cells to facilitate engraftment. PBMCs and CD34+ HSC are collected and purified at our state-of-the-art facility from IRB-consented donors recruited from our robust network of recallable, reliable donors.
Peripheral blood mononuclear cells (PBMCs)
- Quick engraftment, 7-10 days
- Majority of immune cells present are of human T-cell origin (CD4+ and CD8+)
- Ideal for short-term studies
- T and NK cell activity assessments
- Test in vivo antitumor efficacy of immunotherapies which target T and NK cell function using cell line derived xenografts or fast-growing PDX tumors
- PBMCs in a variety of concentrations are available for screening
CD34+ Hematopoietic Stem Cells
- CD34+ HSC demonstrate efficient and stable reconstitution of T cells, NK cells, and B cells, as well as myeloid cells
- Engraftment takes significantly longer but results in stable, long-term humanization, with minimal risk of GVHD
- Complex biological evaluations where longer longitudinal analyses are required, such as memory T cell response and human tumor-bearing models
- Cord blood, bone marrow, and mobilized peripheral blood CD34+ cells available
NCG Mouse Model
Immunodeficient mouse models that support multilineage human immune cell reconstitution embody a more biologically relevant simulation of human immune response. The NCG mouse model is Charles River’s most immunodeficient model to date. This humanized mouse model was created by sequential CRISPR/Cas9 editing of the Prkdc and Il2rg loci in the NOD/Nju mouse, generating a mouse coisogenic to the NOD/Nju. The NOD/Nju carries a mutation in the Sirpa (SIRP α) gene that allows for engrafting of foreign hematopoietic stem cells. The Prkdc knockout generates a SCID-like phenotype lacking proper T-cell and B-cell formation. The knockout of the Il2rg gene further exacerbates the SCID-like phenotype while additionally resulting in a decrease of NK cell production. For more information or to order the NCG mouse, click here.
NCG/PBMC Select Humanization Kit
PBMC mouse model humanization made easier, faster, and more reliable
Successful engraftment of PBMCs can differ with each donor, making immune response frustratingly variable. As such, significant qualification efforts are required to determine optimal donors. By providing a “kit” of preselected cells and mice, researchers save time and resources short-term spent on characterizing PBMCs putting them in control of study timing, a distinct advantage when dealing with a limited therapeutic window.
- PBMCs prescreened for engraftment rate, body weight loss, and study term
- Cell numbers optimized for use in the NCG mouse model
- PBMCs easily transplanted via tail vein injection
- Donors chosen to minimize study losses and measurable response while maximizing engraftment
